Literature DB >> 10441119

Structure of the extended-spectrum class C beta-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion.

G V Crichlow1, A P Kuzin, M Nukaga, K Mayama, T Sawai, J R Knox.   

Abstract

A class C beta-lactamase from a clinical isolate of Enterobacter cloacae strain GC1 with improved hydrolytic activity for oxyimino beta-lactam antibiotics has been analyzed by X-ray crystallography to 1.8 A resolution. Relative to the wild-type P99 beta-lactamase, this natural mutant contains a highly unique tandem repeat Ala211-Val212-Arg213 [Nugaka et al. (1995) J. Biol. Chem. 270, 5729-5735]. The 39.4 kDa chromosomal beta-lactamase crystallizes from poly(ethylene glycol) 8000 in potassium phosphate in space group P2(1)2(1)2 with cell dimensions a = 78.0 A, b = 69.5 A, and c = 63.1 A. The crystal structure was solved by the molecular replacement method, and the model has been refined to an R-factor of 0.20 for all nonzero data from 8 to 1.8 A. Deviations of model bonds and angles from ideal values are 0.008 A and 1.4 degrees, respectively. Overlay of alpha-carbon atoms in the GC1 and P99 beta-lactamases results in an rms deviation of 0.6 A. Largest deviations occur in a loop containing Gln120 and in the Omega loop region (200-218) where the three residues 213-215 are disordered. Possibly as a result of this disorder, the width of the opening to the substrate binding cavity, as measured from the 318-324 beta-strand to two loops containing Gln120 and Tyr150 on the other side, is 0.6-1.4 A wider than in P99. It is suggested that conformational flexibility in the expanded Omega loop, and its influence on adjacent protein structure, may facilitate hydrolysis of oxyimino beta-lactams by making the acyl intermediate more open to attack by water. Nevertheless, backbone atoms in core catalytic site residues Ser64, Lys67, Tyr150, Asn152, Lys318, and Ser321 deviate only 0.4 A (rmsd) from atoms in P99. A rotation of a potential catalytic base, Tyr150, relative to P99 at pH 8, is consistent with the requirement for a lower than normal pK(a) for this residue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441119     DOI: 10.1021/bi9908787

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  36 in total

1.  Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors.

Authors:  Donatella Tondi; Samuele Calò; Brian K Shoichet; Maria Paola Costi
Journal:  Bioorg Med Chem Lett       Date:  2010-04-09       Impact factor: 2.823

2.  Identification of residues critical for catalysis in a class C beta-lactamase by combinatorial scanning mutagenesis.

Authors:  Shalom D Goldberg; William Iannuccilli; Tuan Nguyen; Jingyue Ju; Virginia W Cornish
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

3.  Exact location of the region responsible for the extended substrate spectrum in class C beta-lactamases.

Authors:  Sang Hee Lee; Jung Hun Lee; Myong Jin Heo; Il Kwon Bae; Seok Hoon Jeong; Sun-Shin Cha
Journal:  Antimicrob Agents Chemother       Date:  2007-10       Impact factor: 5.191

4.  Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.

Authors:  Stathis D Kotsakis; Costas C Papagiannitsis; Eva Tzelepi; Leonidas S Tzouvelekis; Vivi Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

5.  Naturally occurring extended-spectrum cephalosporinases in Escherichia coli.

Authors:  Hedi Mammeri; Laurent Poirel; Nicolas Fortineau; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  EstB from Burkholderia gladioli: a novel esterase with a beta-lactamase fold reveals steric factors to discriminate between esterolytic and beta-lactam cleaving activity.

Authors:  Ulrike G Wagner; Evamaria I Petersen; Helmut Schwab; Christoph Kratky
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

7.  Kinetic properties of four plasmid-mediated AmpC beta-lactamases.

Authors:  Cédric Bauvois; Akiko Shimizu Ibuka; Almeida Celso; Jimena Alba; Yoshikazu Ishii; Jean-Marie Frère; Moreno Galleni
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

8.  Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.

Authors:  Sushmita D Lahiri; Richard A Alm
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 9.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

10.  Interactions of oximino-substituted boronic acids and β-lactams with the CMY-2-derived extended-spectrum cephalosporinases CMY-30 and CMY-42.

Authors:  Stathis D Kotsakis; Emilia Caselli; Leonidas S Tzouvelekis; Efi Petinaki; Fabio Prati; Vivi Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.